Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

Abstract

Our analysis indicates that the incidence of SCLC is decreasing in the United States, and only modest improvements have been seen in survival over the last 30 years. Possible explanations for the decreasing incidence include the decrease in the percentage of smokers and the change to low-tar filter cigarettes. Despite trends toward modest improvement in survival, the outcome remains very poor.

Novel Approaches of Chemoradiotherapy in Unresectable Stage IIIA and Stage IIIB Non-Small Cell Lung Cancer

“…The majority of patients with lung cancer have the non-small cell lung cancer (NSCLC) subtype, and approximately one third of patients have unresectable stage IIIA or stage IIIB disease [3]. Patients with a preserved performance status, with adequate organ function, and without significant weight loss are candidates for chemoradiotherapy with curative intent.…”

Prognostic Factors for Survival of Patients with Extensive Stage Small Cell Lung Cancer - a Retrospective Single Institution Analysis

“…Small cell lung cancer (SCLC) accounts for approximately 15% to 18% of all lung cancers and is highly-associated with smoking (Khuder, 2001;Govindan et al, 2006). According to Neal et al, the Veterans Administration Lung Study Group staging system divides SCLC into limited stage (LS) and extensive stage (ES) disease (Neal et al, 2011).…”

Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study

“…3 These tumors considerably differ in their biological behaviors, thus, they are classified as either low-grade typical carcinoids, intermediate-grade atypical carcinoids, high-grade large cell neuroendocrine lung cancer, or small cell lung cancer. 3,4 Small cell lung cancers account for the largest group of these tumors (B15% of all lung malignancies) and are associated with an extremely poor prognosis, [5][6][7][8] whereas large cell euroendocrine cancers and carcinoids are rare. Currently, the 2004 World Health Organization classification of pulmonary neuroendocrine tumors is based on combined architectural patterns considering the two most relevant morphological parameters, that is, the mitotic index and the presence of necrosis, diagnosed by haematoxylin and eosin morphology.…”